

Abstract

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP α), said prodrug having a cleavage site which is recognised by FAP α , and said drug being cytotoxic or cytostatic under physiological conditions.